Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +50.33%
#3 Black Phoenix Black Phoenix +34.86%
#4 Velvet Velvet +32.55%
#5 Akedo Akedo +22.72%
#6 Fake World Assets Fake World Assets +19.66%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.95%
#8 DoubleZero DoubleZero +16.74%
#9 Palladium Network Palladium Network +15.82%
#10 clBTC clBTC +11.69%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
PCI Biotech Holding ASA PCI Biotech Holding ASA

PCI Biotech Holding ASA

PCIB
Rank in Stocks #40013
PCI Biotech Holding ASA, an Oslo, Norway-based biopharmaceutical firm, is... PCI Biotech Holding ASA, an Oslo, Norway-based biopharmaceutical firm, is focused on pioneering and bringing to market innovative treatments for cancer. At the core of their operations is the proprietary photochemical internalization (PCI) technology platform. The company's development pipeline features several distinct therapeutic strategies: fimaCHEM, a novel approach to chemotherapeutic cancer treatment; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is currently in Phase I clinical studies; and fimaNAc, a delivery system for nucleic acid therapeutics, presently in its pre-clinical phase. Furthermore, they provide Amphinex, a photosensitizer known as fimaporfin. PCI Biotech actively participates in joint research endeavors with partners such as Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense.
Share Price
$0.00733708
Last synced: 2026-04-23
Market Cap
$273.87K
Change (1 day)
-39.13%
Change (1 year)
-94.83%
Country
NO
Trade PCI Biotech Holding ASA (PCIB)

Category

Healthcare
Revenue for PCI Biotech Holding ASA (PCIB)
Revenue in Aug 2026 TTM: 0
According to PCI Biotech Holding ASA latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for PCI Biotech Holding ASA from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE